532 related articles for article (PubMed ID: 30231396)
21. Minimizing cardiac toxicity in children with acute myeloid leukemia.
Narayan HK; Getz KD; Leger KJ
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):368-375. PubMed ID: 34889355
[TBL] [Abstract][Full Text] [Related]
22. Dexrazoxane: a cardioprotectant for pediatric cancer patients receiving anthracyclines.
Wu V
J Pediatr Oncol Nurs; 2015; 32(3):178-84. PubMed ID: 25366577
[TBL] [Abstract][Full Text] [Related]
23. Genetic factors in anthracycline-induced cardiotoxicity in patients treated for pediatric cancer.
Petrykey K; Andelfinger GU; Laverdière C; Sinnett D; Krajinovic M
Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):865-883. PubMed ID: 32772754
[TBL] [Abstract][Full Text] [Related]
24. Anthracycline Chemotherapy-Induced Cardiotoxicity in Breast Cancer Survivors: A Systematic Review.
Lin KJ; Lengacher CA
Oncol Nurs Forum; 2019 Sep; 46(5):E145-E158. PubMed ID: 31424455
[TBL] [Abstract][Full Text] [Related]
25. [Treatment-related cardiotoxicity in childhood cancer survivors: Risk factors and follow-up].
Fresneau B; Fayech C; Butel T; Haddy N; Valteau-Couanet D; Ou P
Rev Med Interne; 2017 Feb; 38(2):125-132. PubMed ID: 27639916
[TBL] [Abstract][Full Text] [Related]
26. Epidemiology of anthracycline cardiotoxicity in children and adults.
Grenier MA; Lipshultz SE
Semin Oncol; 1998 Aug; 25(4 Suppl 10):72-85. PubMed ID: 9768828
[TBL] [Abstract][Full Text] [Related]
27. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer.
van Dalen EC; Raphaël MF; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2009 Jan; (1):CD006647. PubMed ID: 19160293
[TBL] [Abstract][Full Text] [Related]
28. Risk stratification and pattern of cardiotoxicity in pediatric Ewing sarcoma.
Moussa E; Zamzam M; Kamel A; Salah Z; Attia I; Gaber L; Soliman R; Ezzat S
J Egypt Natl Canc Inst; 2017 Mar; 29(1):53-56. PubMed ID: 28258912
[TBL] [Abstract][Full Text] [Related]
29. A critical risk-benefit assessment argues against the use of anthracyclines in induction regimens for newly diagnosed childhood acute lymphoblastic leukemia.
Messinger Y; Uckun FM
Leuk Lymphoma; 1999 Aug; 34(5-6):415-32. PubMed ID: 10492065
[TBL] [Abstract][Full Text] [Related]
30. [Cardiotoxicity of anthracyclines].
Costache II; Petriş A
Rev Med Chir Soc Med Nat Iasi; 2011; 115(4):1200-7. PubMed ID: 22276470
[TBL] [Abstract][Full Text] [Related]
31. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
Chung WB; Youn HJ
Korean J Intern Med; 2016 Jul; 31(4):625-33. PubMed ID: 27378126
[TBL] [Abstract][Full Text] [Related]
32. Subclinical anthracycline-induced cardiotoxicity in long-term follow-up of asymptomatic childhood cancer survivors: Assessment by speckle tracking echocardiography.
Çetin S; Babaoğlu K; Başar EZ; Deveci M; Çorapçıoğlu F
Echocardiography; 2018 Feb; 35(2):234-240. PubMed ID: 29106752
[TBL] [Abstract][Full Text] [Related]
33. Preliminary testing of anthracycline-induced cardiotoxicity in children.
Pejcic L; Vasic K
J BUON; 2017; 22(6):1611-1612. PubMed ID: 29332369
[No Abstract] [Full Text] [Related]
34. Exercise echocardiography in asymptomatic survivors of childhood cancer treated with anthracyclines: a prospective follow-up study.
Sieswerda E; Kremer LC; Vidmar S; De Bruin ML; Smibert E; Sjöberg G; Cheung MM; Weintraub RG
Pediatr Blood Cancer; 2010 Apr; 54(4):579-84. PubMed ID: 20014238
[TBL] [Abstract][Full Text] [Related]
35. Metabolic Aspects of Anthracycline Cardiotoxicity.
Russo M; Della Sala A; Tocchetti CG; Porporato PE; Ghigo A
Curr Treat Options Oncol; 2021 Feb; 22(2):18. PubMed ID: 33547494
[TBL] [Abstract][Full Text] [Related]
36. Late-onset cardiomyopathy among survivors of childhood lymphoma treated with anthracyclines: a systematic review.
Benetou DR; Stergianos E; Geropeppa M; Ntinopoulou E; Tzanni M; Pourtsidis A; Petropoulos AC; Georgakis MK; Tousoulis D; Petridou ET
Hellenic J Cardiol; 2019; 60(3):152-164. PubMed ID: 30273645
[TBL] [Abstract][Full Text] [Related]
37. Pathogenesis of cardiotoxicity induced by anthracyclines.
Elliott P
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S2-7. PubMed ID: 16781283
[TBL] [Abstract][Full Text] [Related]
38. Anthracycline cardiotoxicity.
Menna P; Paz OG; Chello M; Covino E; Salvatorelli E; Minotti G
Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S21-36. PubMed ID: 21635149
[TBL] [Abstract][Full Text] [Related]
39. Cardiotoxicity and cardioprotection in childhood cancer.
Lipshultz SE; Sambatakos P; Maguire M; Karnik R; Ross SW; Franco VI; Miller TL
Acta Haematol; 2014; 132(3-4):391-9. PubMed ID: 25228565
[TBL] [Abstract][Full Text] [Related]
40. Maximizing anthracycline tolerability in hematologic malignancies: Treat to each heart's content.
Oliveira GH; Al-Kindi SG; Caimi PF; Lazarus HM
Blood Rev; 2016 May; 30(3):169-78. PubMed ID: 26578029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
